Detection of MMP-2 and MMP-9 activity in vivo with a triple-helical peptide optical probe.
暂无分享,去创建一个
Samuel Achilefu | Gregg B Fields | Walter J Akers | Gail P Sudlow | Hyeran Lee | S. Achilefu | G. Sudlow | G. Fields | W. Akers | W. B. Edwards | Baogang Xu | Hyeran Lee | Baogang Xu | W Barry Edwards | Samuel | Achilefu
[1] W. Heindel,et al. Synthesis and evaluation of a novel fluorescent photoprobe for imaging matrix metalloproteinases. , 2008, Bioconjugate chemistry.
[2] Z. Werb,et al. How matrix metalloproteinases regulate cell behavior. , 2001, Annual review of cell and developmental biology.
[3] G. Fields,et al. Solid‐Phase synthesis and stability of triple‐helical peptides incorporating native collagen sequences , 1993, Biopolymers.
[4] G. Fields,et al. Use of Edman degradation sequence analysis and matrix-assisted laser desorption/ionization mass spectrometry in designing substrates for matrix metalloproteinases. , 2000, Journal of chromatography. A.
[5] Y. Okada,et al. Enhanced production of matrix metalloproteinases and activation of matrix metalloproteinase 2 (gelatinase A) in human gastric carcinomas , 1996, International journal of cancer.
[6] R. Weissleder,et al. In vivo imaging of tumors with protease-activated near-infrared fluorescent probes , 1999, Nature Biotechnology.
[7] Samuel Achilefu,et al. Heptamethine cyanine dyes with a robust C-C bond at the central position of the chromophore. , 2006, The Journal of organic chemistry.
[8] R. Klebe,et al. Overview of matrix metalloproteinase expression in cultured human cells. , 1998, Matrix biology : journal of the International Society for Matrix Biology.
[9] M. Radomski,et al. N-substituted homopiperazine barbiturates as gelatinase inhibitors. , 2011, Bioorganic & medicinal chemistry.
[10] E. Baker,et al. Measuring gelatinase activity in colorectal cancer. , 2002, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[11] J. Foidart,et al. Assay of matrix metalloproteinases types 1, 2, 3 and 9 in breast cancer. , 1998, British Journal of Cancer.
[12] Christoph Abels,et al. Absorption and Fluorescence Spectroscopic Investigation of Indocyanine Green , 1996 .
[13] R Weissleder,et al. In vivo imaging of proteolytic enzyme activity using a novel molecular reporter. , 2000, Cancer research.
[14] Matthew Tirrell,et al. Self-assembling amphiphiles for construction of protein molecular architecture , 1996 .
[15] D. Leaper,et al. Matrix metalloproteinases, their tissue inhibitors and colorectal cancer staging , 2000, The British journal of surgery.
[16] Daniel J. Hawrysz,et al. Developments toward diagnostic breast cancer imaging using near-infrared optical measurements and fluorescent contrast agents. , 2000, Neoplasia.
[17] E. Novellino,et al. Synthesis and biological evaluation in U87MG glioma cells of (ethynylthiophene)sulfonamido-based hydroxamates as matrix metalloproteinase inhibitors. , 2011, European journal of medicinal chemistry.
[18] Ralph Weissleder,et al. Near-infrared optical imaging of proteases in cancer. , 2003, Molecular cancer therapeutics.
[19] D. Grignon,et al. Membrane type 1-matrix metalloproteinase (MT1-MMP) and MMP-2 immunolocalization in human prostate: change in cellular localization associated with high-grade prostatic intraepithelial neoplasia. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[20] C. Bucana,et al. Relative expression of type IV collagenase, E-cadherin, and vascular endothelial growth factor/vascular permeability factor in prostatectomy specimens distinguishes organ-confined from pathologically advanced prostate cancers. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[21] Z. Werb,et al. Matrix metalloproteinases contribute distinct roles in neuroendocrine prostate carcinogenesis, metastasis, and angiogenesis progression. , 2010, Cancer research.
[22] B. Packard,et al. Profluorescent protease substrates: intramolecular dimers described by the exciton model. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[23] Ralph Weissleder,et al. In vivo molecular target assessment of matrix metalloproteinase inhibition , 2001, Nature Medicine.
[24] R. Leblanc,et al. Analysis of matrix metalloproteinase triple-helical peptidase activity with substrates incorporating fluorogenic L- or D-amino acids. , 2003, Analytical biochemistry.
[25] I. Nishimoto,et al. Expression of gelatinases A and B, stromelysin-3 and matrilysin genes in breast carcinomas: clinico-pathological correlations , 1998, Clinical & Experimental Metastasis.
[26] D. Ruiter,et al. Matrix metalloproteinases in human melanoma. , 2000, The Journal of investigative dermatology.
[27] P. Wielopolski,et al. Multimodality Imaging Reveals a Gradual Increase in Matrix Metalloproteinase Activity at Aneurysmal Lesions in Live Fibulin-4 Mice , 2010, Circulation. Cardiovascular imaging.
[28] M. Stack,et al. Selective Hydrolysis of Triple-helical Substrates by Matrix Metalloproteinase-2 and -9* , 2003, The Journal of Biological Chemistry.
[29] Raghu Kalluri,et al. Fibroblasts in cancer , 2006, Nature Reviews Cancer.
[30] H. Verspaget,et al. Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. , 1996, British Journal of Cancer.
[31] K. Nicolay,et al. Tumor Targeting of MMP-2/9 Activatable Cell-Penetrating Imaging Probes Is Caused by Tumor-Independent Activation , 2011, The Journal of Nuclear Medicine.
[32] Shiva Gautam,et al. Development of a novel fluorogenic proteolytic beacon for in vivo detection and imaging of tumour-associated matrix metalloproteinase-7 activity. , 2004, The Biochemical journal.
[33] Molecular imaging of MMP expression and therapeutic MMP inhibition. , 2002, Academic radiology.
[34] J. Becker,et al. Coexpression of Integrin αvβ3 and Matrix Metalloproteinase-2 (MMP-2) Coincides with MMP-2 Activation: Correlation with Melanoma Progression , 2000 .
[35] Hamid Dehghani,et al. Endoscopic, rapid near-infrared optical tomography. , 2006, Optics letters.
[36] Ralph Weissleder,et al. Developing a peptide-based near-infrared molecular probe for protease sensing. , 2004, Bioconjugate chemistry.
[37] M. Kaiser-Kupfer,et al. Retinal visualization in an eye with corneal crystals using indocyanine green videoangiography. , 2002, American journal of ophthalmology.
[38] Dominique Trudel,et al. Significance of MMP-2 expression in prostate cancer: an immunohistochemical study. , 2003, Cancer research.
[39] J. Becker,et al. Expression and activation of matrix metalloproteinase‐2 (MMP‐2) and its co‐localization with membrane‐type 1 matrix metalloproteinase (MT1‐MMP) correlate with melanoma progression , 2000 .
[40] Samuel Achilefu,et al. Monitoring the biodegradation of dendritic near-infrared nanoprobes by in vivo fluorescence imaging. , 2008, Molecular pharmaceutics.
[41] T. Turpeenniemi‐Hujanen,et al. Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma , 2003, British Journal of Cancer.
[42] E. Kubista,et al. MMP-2 and MMP-9 Expression in Breast Cancer-Derived Human Fibroblasts is Differentially Regulated by Stromal-Epithelial Interactions , 2002, Breast Cancer Research and Treatment.
[43] Roger Y Tsien,et al. Systemic in vivo distribution of activatable cell penetrating peptides is superior to that of cell penetrating peptides. , 2009, Integrative biology : quantitative biosciences from nano to macro.
[44] M. Schaefer,et al. Low Molecular Weight Inhibitors in Corneal Ulceration a , 1994, Annals of the New York Academy of Sciences.
[45] J. Seltzer,et al. Cleavage specificity of human skin type IV collagenase (gelatinase). Identification of cleavage sites in type I gelatin, with confirmation using synthetic peptides. , 1990, The Journal of biological chemistry.
[46] A Yasui,et al. Matrix metalloproteinase 2 from human rheumatoid synovial fibroblasts. Purification and activation of the precursor and enzymic properties. , 1990, European journal of biochemistry.
[47] Xiaojuan Li,et al. Characterization of Human Osteoarthritic Cartilage Using Optical and Magnetic Resonance Imaging , 2011, Molecular Imaging and Biology.
[48] S. Mobashery,et al. Sulfonate-containing thiiranes as selective gelatinase inhibitors. , 2011, ACS medicinal chemistry letters.
[49] L. Matrisian,et al. Imaging matrix metalloproteinases in cancer , 2008, Cancer and Metastasis Reviews.
[50] A. Popel,et al. A Biochemical Model of Matrix Metalloproteinase 9 Activation and Inhibition* , 2007, Journal of Biological Chemistry.
[51] P. Glynn,et al. Expression of MMP‐2 and MMP‐9, their inhibitors, and the activator MT1‐MMP in primary breast carcinomas , 1999, The Journal of pathology.
[52] Z. Werb,et al. New functions for the matrix metalloproteinases in cancer progression , 2002, Nature Reviews Cancer.